CFO
NBIX icon

Callan Family Office’s Neurocrine Biosciences NBIX Stock Holding History

Callan Family Office’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$476K Buy
2,824
+31
+1% +$4.6K 0.01% 837
2026
Q1 		$368K Sell
2,793
-2,933
-51% -$389K 0.01% 863
2025
Q4 		$812K Buy
5,726
+3,814
+199% +$553K 0.02% 611
2025
Q3 		$268K Sell
1,912
-358
-16% -$48.5K 0.01% 743
2025
Q2 		$285K Buy
+2,270
New +$260K 0.01% 783

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Callan Family Office's NBIX Position: Q2 2026 in Review

Callan Family Office increased its Neurocrine Biosciences (NBIX) stake by 1.1% in Q2 2026, buying an estimated $4.6K and bringing the position to 2,824 shares worth $476K. The position accounts for 0.01% of the portfolio, ranked #837.

Callan Family Office first reported a position in NBIX in Q2 2025 and has held it in 5 quarters since. The position peaked at $812K in Q4 2025. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Callan Family Office held 2,824 shares of Neurocrine Biosciences worth $476K as of Q2 2026.
  • Callan Family Office bought 31 Neurocrine Biosciences shares in Q2 2026, an estimated $4.6K.
  • Neurocrine Biosciences made up 0.01% of Callan Family Office's portfolio in Q2 2026, its #837 holding.
  • Callan Family Office first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Callan Family Office's Neurocrine Biosciences position peaked at $812K in Q4 2025.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.